During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

French cell therapy company Celyad is also working in the area, its lead candidate CYAD-01 is an autologous CAR-T NKG2D therapy for use in haematological and solid cancers.

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Researchers explore the cellular and molecular adaptations associated with human secondary lymphoid tissue in adults during ...

Brain Tumor Organoids Accurately Model Patient Response to CAR T Cell Therapy Dec. 9, 2024 — Researchers used lab-grown organoids created from tumors of individuals with glioblastoma (GBM ...

For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis ...

See a doctor who has experience with it. You’ll find dermatologists who have experience with cutaneous T-cell lymphoma at Find a Dermatologist. Click on "Filters". Select "Any condition" and choose ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

31, 2025 — Prolonged illnesses like cancer and chronic infections often leave the immune system in a state of exhaustion, where its frontline defenders -- T cells -- lose their ability to ...